跳至主要内容
临床试验/NCT01227980
NCT01227980已完成2 期

Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics

National Institute on Alcohol Abuse and Alcoholism (NIAAA)1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2010年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
70
试验地点
1
主要终点
Alcohol Craving in Response to the Alcohol Cue Script

研究概览

简要总结

Background:

  • Individuals who are dependent on alcohol often have feelings of anxiety, irritability, anger, and depression. These feelings, as well as stress, may contribute to the risk of relapse and continued drinking. Studies have shown that alcohol consumption increases the activity of certain molecules in the brain known as CRH1 receptors, which are key to producing the body s response to stress, and whose activation generates feelings of anxiety. Researchers are interested in learning whether the experimental drug pexacerfont, which blocks CRH1 receptors and has been studied in individuals with anxiety disorders and depression, can lessen anxiety and craving for alcohol as part of alcohol-dependence treatment.

Objectives:

  • To determine the safety and effectiveness of pexacerfont as a treatment for anxiety-related alcohol craving.

Eligibility:

  • Individuals between 21 and 65 years of age who are alcohol-dependent and have problems with anxiety.

Design:

  • This study requires an inpatient admission to the NIH Clinical Center for approximately 1 month, with two additional study visits 1 week and 1 month after discharge from the hospital.
  • Participants will be screened with a medical history, physical examination, and blood and urine tests.
  • During the inpatient period, participants will have standard treatment for alcohol dependence, including support and interventions from institute staff to address cravings, anxiety, or other psychological problems. Participants will not receive formal psychological treatment or psychiatric medications for anxiety, but will receive training in relaxation techniques.
  • Participants will be assigned to take either pexacerfont or placebo for 3 weeks. During this time, participants will have the following procedures:
  • Frequent blood tests.
  • Rating scales and questionnaires about alcohol cravings and anxiety.
  • Dexamethasone suppression test with frequent blood draws to study hormone response to stress.
  • Social stress test involving public speaking, followed by blood samples and questionnaires on alcohol craving.
  • Cue Reactivity (CR) session to study cravings and responses to alcohol-based cues.
  • Functional magnetic resonance imaging scan to evaluate brain activity while taking the medication or placebo.
  • Participants will have two follow-up visits for additional blood tests and questionnaires about the effects of the treatment ^.

详细描述

OBJECTIVE :

To evaluate pexacerfont, an orally available, brain penetrant selective CRH1 antagonist for its ability to modulate emotional and motivational processes in anxious, recently detoxified alcohol dependent patients.

STUDY POPULATION:

Up to 70 anxious, alcohol dependent subjects, aged 21-65 years will be enrolled to complete the study in 50 patients.

DESIGN

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
21 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Pexacerfont

Active Comparator

Pexacerfont was given orally as a loading dose of 300 mg/day for 1 week, followed by 100mg/day for 16-20 days

干预措施: Pexacerfont (Drug)

Placebo

Placebo Comparator

Oral placebo was given during the 1-week loading dose phase, and during the next 16-20 days

干预措施: Placebo (Drug)

结局指标

主要结局

Alcohol Craving in Response to the Alcohol Cue Script

时间窗: 90 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value).

Alcohol Craving in Response to the Stress Script

时间窗: 90 minutes after the beginning of script presentation, which occurred on Day 24, 25, or 26 of the treatment period

Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ). The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now). The score ranges from 8 (lowest craving value) to 56 (highest craving value).

次要结局

未报告次要终点

研究者

发起方
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
申办方类型
Nih
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验